Systemic therapy of corticosteroids and immunosuppressants better preserved vision in patients with uveitis compared to Bausch & Lomb‘s long-lasting corticosteroid intraocular implant in a clinical trial supported by the National Eye Institute, a branch of the National Institutes of Health.
In 7 years, visual acuity remained stable in patients receiving systemic therapy and declined by an average of 1 line on an eye chart among patients with the implant, according to the study.
Get the full story at our sister site, Drug Delivery Business News.
The post Systemic therapy beats Bausch & Lomb implant in NIH uveitis study appeared first on MassDevice.